Global stock

NYSEUSD

HCA Healthcare

HCA

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

68/ 100

Overall score·HCA

Current price

465.26USD

26/10/2026

P/E, P/B

Valuation

Strong

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

P/E 15,4 a EV/EBITDA 9,7 působí ve srovnání s širším trhem umírněně, zatímco PEG 1,43 ukazuje na ocenění, které již část růstu zohledňuje. Silnými stránkami jsou růst EPS a tržeb i provozní marže; slabší je stabilita, zejména kvůli likviditě pod 1 a chybějícím údajům o zadlužení.

§ Outlook vs S&P 500Next 12 months

Probably yes

Estimated chance of beating the index: about 67%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at HCA Healthcare (HCA) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

68/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

70/100

Slightly positive signal based on current news, price action and the economy.

70/100

A lower score means the stock is expensive relative to the company's earnings and assets.

27% below fair value

An estimate of what the stock should be worth based on the company's future cash.

+9%

How fast the company's revenue grows year on year.

72/100

How much the company earns from each unit of revenue and from invested capital.

54/100

Debt level, share-price volatility and how resilient the company is in bad times.

72/100

AI estimate of management quality, execution and capital allocation.

70/100

AI estimate of the company's durable competitive advantage.

§ Financial results

Financial results·HCA

mld. USD

RevenueEBITDANet incomeEBITDA margin

Margins and profitability·HCA

Net marginEBITDA marginDashed = estimate

Net margin

+9.0 %

FY 2025 · reported

EBITDA margin

+20.6 %

FY 2026 · estimate

Net margin

+8.8 %

last 12 months

Operating margin

+15.2 %

last 12 months

ROE

—

Not available

FY = fiscal year · TTM = trailing 12 months

§ Context and events

Management

Samuel N. Hazen je CEO a člen představenstva, Michael A. Marks zastává funkci CFO a výkonného viceprezidenta. Jon Mack Foster je výkonný viceprezident a COO; Michael R. McAlevey vede právní a administrativní oblast. Strategie HCA stojí na provozu rozsáhlé sítě zdravotnických zařízení a řízení efektivity, kapacit a investic.

Articles about HCA Healthcare, in Czech (1)

HCA Healthcare překonala odhady za třetí čtvrtletí a drží výhled

HCA Healthcare ve třetím čtvrtletí zvýšila upravený zisk na akcii na 7,22 dolaru a tržby na 19,85 miliardy dolarů, čímž překonala odhady. Firma ponechala celoroční výhled a čeká výsledky v jeho horní polovině.

27 October 2026· 2 min

§ Upcoming results

27 October 2026

Today

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is HCA Healthcare (HCA)?

HCA Healthcare (HCA) is a global stock traded on NYSE. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the HCA Healthcare price today?

As of 26 October 2026, HCA Healthcare trades at about 465.26 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy HCA Healthcare?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does HCA Healthcare pay a dividend?

HCA Healthcare either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is HCA Healthcare a good investment in 2026?

Our AI signal currently rates HCA Healthcare as slightly positive (score 70/100). Financial health comes out at 68/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 27 % below its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy HCA Healthcare

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

§ Recent article

27/10 · 2 min

HCA Healthcare překonala odhady za třetí čtvrtletí a drží výhled

Open article →

/ 100

● Slightly positive

Earnings today

On 27 October 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Fresh news

Signal 27/10, 17:02

HCA oznámila vyšší upravený zisk i tržby za 3. čtvrtletí; akcie v předobchodní fázi rostly o více než 2 %. Udržení růstu závisí na potvrzení výhledu.

Pozitivní výsledky doprovází růst akcie za 7 i 30 dní a vzestupný trend; momentum je však jen mírné. Dlouhodobý výhled omezuje citlivost nemocničního provozu na náklady a úhrady.

Risks: Pokud se růst nákladů nebo tlak nezajištěných pacientů promítne do slabšího výhledu či marží, pozitivní signál může rychle zeslábnout.

More about the signal

Pozitivní výsledky doprovází růst akcie za 7 i 30 dní a vzestupný trend; momentum je však jen mírné. Dlouhodobý výhled omezuje citlivost nemocničního provozu na náklady a úhrady.

Risks: Pokud se růst nákladů nebo tlak nezajištěných pacientů promítne do slabšího výhledu či marží, pozitivní signál může rychle zeslábnout.

Signal history· 2

27/1013:0257 · Slightly positiveArticle →
HCA zveřejnila čtvrtletní výsledky; jejich dopad závisí na tom, zda překonají očekávání a potvrdí výhled. Předchozí pokles akcie a tlak nezajištěných pacientů zůstávají protiváhou.
26/1007:0157 · Slightly positive
HCA má 27. října zveřejnit výsledky; historicky po 12 z 19 reportů akcie první den klesla. Reakci může změnit výsledek a výhled oproti očekávání.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Undervalued27% below fair value

640.70

range 509.4 – 826.8

Current price

465.26 USD

26 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

640.70 USD

range 509.4 USD – 826.8 USD

: 6.5%
: 9.0%
: 34.25 USD

Růst FCF 6,5 % p.a. je konzervativnější než aktuální růst tržeb a EPS a zohledňuje vyzrálost firmy i nejistotu ve zdravotnictví. Diskontní sazba 9 % odráží mírně nadprůměrné tržní riziko; terminální růst 2,5 % odpovídá dlouhodobému tempu růstu ekonomiky. Model při těchto předpokladech naznačuje hodnotu založenou na pětileté projekci.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 15 of 18

Valuation score

4/ 6

6/6 tests available

1. Below DCF fair value

27.4% below the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

57% above the 1-year low (361.3 USD to 545.1 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 15.4 vs. median 26.7 (71 companies).

5. P/E relative to growth

PEG 1.4; a lower value means cheaper growth.

6. Analyst price target

-1.0% vs. the current price, 22 analysts.

Price vs DCF

Current price

465.3 USD

Low 509.4 USDHigh 826.8 USD

Current priceDCF midpoint: 640.7 USD

Price vs analyst target

Current price

465.3 USD

Low 380.0 USDHigh 579.0 USD

Current priceAverage: 460.6 USD

DCF gap

below range

27.4% below the DCF midpoint (640.7 USD).

Analyst target

-1.0%

Average target 460.6 USD vs. price 465.3 USD.

Analyst consensus

Target range

380.0 USD - 579.0 USD

Coverage

22 analysts

Analyst consensus

2 / 5

Changes 180 d

+0 / -1

EPS next year

8.6%

Revenue next year

3.9%

Valuation multiples

15.4

14.3

1.3

9.7

1.4

52-week range57% above the low

361.3 USD545.1 USD

12.0%

9.0%

8.8%

Price vs 50D9.3%

Price vs 200D4.6%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

strong

Vedení vykazuje solidní provozní exekuci a pokračuje v regionální expanzi i modernizaci zařízení, avšak zvýšená governance rizika u auditu a správní rady skóre snižují.

strong

Rozsáhlá síť nemocnic a ambulantních zařízení přináší HCA výhodu rozsahu, regionální dosah a návaznost péče. Konkurenční výhodu však omezují regulace a konkurence dalších poskytovatelů zdravotní péče.

Information

Type: Global stock
Symbol: HCA
Exchange: NYSE
Currency: USD
Sector: Healthcare
: 15.4x
: 101.8B USD
: 1.11

§ Risk profile

Výsledky HCA mohou zatížit růst mezd a dalších provozních nákladů, změny úhrad pojišťoven či regulace a vysoké kapitálové výdaje. Českému investorovi navíc kolísá korunová hodnota investice podle kurzu dolaru.

Ask the AI about HCA Healthcare All signals